The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection

Clinical Infectious Diseases

Volumn 46, Issue 10, 2008, Pages 1489-1492

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; FUSIDIC ACID; METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; CONFERENCE PAPER; DRUG COST; DRUG DOSE REDUCTION; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HOSPITAL COST; HUMAN; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RELAPSE; STANDARD; TREATMENT DURATION; TYPHLITIS; DRUG EFFECT; HISTORY; MICROBIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; METRONIDAZOLE; VANCOMYCIN;

EID: 43249096532     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587654     Document Type: Conference Paper

References (35)

1. Hummel RP, Altemeier WA, Hill EO. Iatrogenic staphylococcal enterocolitis. Ann Surg 1964; 160:551-60.
2. Altemeier WA, Hummel RP, Hill EO. Staphylococcal enterocolitis following antibiotic therapy. Ann Surg 1963; 157:847-58.
3. Khan MY, Hall WH. Staphylococcal enterocolitis: treatment with oral vancomycin. Ann Intern Med 1966; 65:1-8.
4. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med 1974; 8:1429-33.
5. Browne RA, Fekety R Jr, Silva J Jr, Boyd DI, Work CO, Abrams GD. The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J 1977; 141:183-92.
6. Bartlett JG, Onderdonk AB, Cisneros RL. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology 1977; 73:772-6.
7. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298:531-4.
8. Mogg GA, Arabi Y, Youngs D, et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl 1980; (Suppl 22):41-5.
9. Pashby NL, Bolton RP, Sheriff RJ. Oral metronidazole in Clostridium difficile colitis. Br Med J 1979; 1:1505-6.
10. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole vs. vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet 1983; 2:1043-6.
11. Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother 1984; 14(Suppl D):97-102.
12. Bartlett JG, Tedesco FJ, Shull S, Lower B, Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980; 78:431-4.
13. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I; European Study Group on Clostridium difficile (ESGCD). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterization of the isolates. Clin Microbiol Infect 2007; 13:1048-57.
14. Hecht DW, Galang MA, Sambol DP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51:2716-9.
15. Barbut F, Decré D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607-11.
16. Peláez T, Alcalá L, Alonso R, Rodríguez- Créixems M, García-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647-50.
17. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999; 34:1-6.
18. Johnson S, Sanchez JL, Gerding DN. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000; 31:625-6.
19. Freeman J, Stott J, Baines SD, Fawley WN, Wilcox MH. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005; 56:988-9.
20. Pham P, Bartlett JG. Vancomycin in Johns Hopkins poc-it HIV guide. McKesson Web site. Available at: http://www.hopkinshivguide.org/drug/ antimicrobial_agents/vancomycin.html. Accessed on 18 March 2008.
21. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997; 25(Suppl 2):S206-10.
22. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102:2781-8.
23. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145:758-64.
24. Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-64.
25. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of rcurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
26. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pscudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36:2192-6.
27. Zar Fa, Bakkanagari kSR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
28. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8.
29. Smith LD, King EO. Occurrence of Clostridium difficile in infections of man. J Bacteriol 1962; 84:65-7.
30. Johnson S. Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomhcin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297-302.
31. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169-72.
32. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-assodicated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
33. Louie T. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [abstract K-4259]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC). Herndon, VA: ASM Press, 2007.
34. Lahue Bj, Davidson DM. Metronidazole and vancomycin outcome for Clostridium difficile-associated diarrhea in a US hospital data base [abstract 1732_215]. In: Program and abstracts of the 17th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Disease (Munich, Germany). 2007.
35. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007; 3:CD004610.